On February 15, the American Institute for Medical and Biological Engineering (AIMBE) officially released the list of AIMBE Fellow of 2021. A total of 174 AIMBE Fellows were elected worldwide in recognition of their outstanding achievements in medicine and biological engineering. 5 Chinese scholars including Prof. Chen Chunying from the National Center for Nanoscience and Technology were elected.
The American Institute for Medical and Biological Engineering (AIMBE) is a world-known non-profit organization, representing the most accomplished individuals in the fields of medical and biological engineering. It has gathered the world's elites in the field of medicine and bioengineering, including 3 Nobel Prize winners, 18 U.S. Presidential Scholar Award winners, 195 fellows of U.S. National Academy of Engineering, 94 fellows of U.S. National Academy of Medicine, and 43 fellows of U.S. National Academy of Sciences. AIMBE Fellows are nominated each year by their peers and represent the top 2% of the medical and biological engineering community. They are considered the life-blood of AIMBE and work towards realizing AIMBE's vision to provide medical and biological engineering innovation for the benefit of humanity. Since AIMBE's inception, over 2,000 esteemed individuals have been inducted to AIMBE's College of Fellows.
Chen Chunying is a professor and PhD supervisor from National Center for Nanoscience and Technology of China. She is the Chief Scientist of the National Key Research & Development Program "Nano Science and Technology" and backbone member of the Innovative Research Groups of the National Natural Science Foundation of China.
Dr. Chen received her Bachelor's degree in chemistry in1991 and obtained her PhD degree in Biomedical engineering from Huazhong University of Science and Technology of China in 1996. She worked as a postdoctoral research fellow at the Key Laboratory of Nuclear Analytical Techniques, Institute of High Energy Physics of Chinese Academy of Sciences and at the Medical Nobel Institute for Biochemistry of Karolinska Institute, Sweden. From 2002 onwards, she is working as a group and project leader at the China Nanosafety lab. Dr. Chen currently is a principal investigator at Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety in National Center for Nanoscience and Technology of China. She is the principle investigator of several domestic and international projects, such as China MOST 973 Program and projects from Natural Science Foundation of China, the EU-FP6 and EU-FP7, IAEA Coordinated Research Project (2009-2012), Danish Council for Strategic Research (2013-2015), Germany BMBF Cooperation Project (2011-2014), and Japan photon factory cooperation projects (2006-2007, 2008-2009). She has served as associate editor and editorial board member of peer-reviewed journals including Science Bulletin, NanoImpact, Metallomics, Nanotoxicology, Particle and Fibre Toxicology, and Current Drug Metabolism. She has won twice the Second Prize of the National Natural Science Award and has been awarded the National Award for Innovation and Outstanding Service to the Standard authorized by Standardization Administration of the People's Republic of China in 2011. In 2014, she has won many awards including the "China Top Ten Young Female Scientist Award", the " National Hundred, Thousand, and Ten Thousand Talents Project", and the "Young and Middle-aged Experts with Outstanding Contributions"; she was also selected as one of Highly Cited Researchers by Thomson Reuters. In 2016, Dr. Chen was elected as Fellow of the Royal Society of Chemistry (FRSC). In 2017, she was elected as the "Top Ten Outstanding Women" by the Chinese Academy of Sciences and elected as one of the Highly Cited Researchers by Clarivate Analytics.
Dr. Chen is mainly engaged in the researches of nano-biological effects and safety evaluation, the construction of new medical nano-materials and their applications in the biomedical field. She has published more than 230 papers in top journals including Nature Nano, JACS, Adv Mater, PNAS, ACS Nano, Small, and Biomaterials. Her works have been cited for more than 28,000 times, with the H-Index of 86 (according to Google Scholar). She has edited 6 Chinese and English monographs, which were published by RSC, Wiley and Science Press. Dr. Chen has been invited to write research progress report for the tenth founding anniversary of Nature Nanotech, and was evaluated as a "leading scientist" in this field. She has applied for 17 invention patents with 17 domestically authorized invention patents and 1 internationally authorized PCT invention patent (U.S., EU, Japan). She is responsible for establishing China's first international nanotechnology standard, which was promulgated by ISO and IEC as a standard for global use.
Dr. Chen's current research interests include: 1) Development of novel nanomedicine with high efficiency and low toxicity for tumor theranostics. 2) Investigation on the interaction of engineered nanomaterials with biological systems. 3) Integrating advanced nuclear techniques and biotechnologies for nanomaterials exposure and molecular mechanisms. 4) Exposure scenarios and the occupational exposure to nanomaterials.
